Trial Profile
An Open-Label, Multicenter, Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2023
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 27 Sep 2022 Planned End Date changed from 5 Mar 2023 to 31 May 2024.
- 27 Sep 2022 Planned primary completion date changed from 5 Mar 2023 to 31 May 2024.
- 08 Oct 2020 Planned End Date changed from 30 Jun 2022 to 5 Mar 2023.